GLP-1 weight loss drugs are increasingly popular as a treatment for obesity. But a lot of employer-sponsored health plans won’t cover the treatments, especially at small and medium-sized firms.
Medicare will get a 71% discount off the list price of Ozempic and Wegovy starting in 2027.
Restaurants and snack companies are moving towards high-protein foods and smaller portions.
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
The drugs are expensive out of pocket. Even with insurance, high co-pays can also limit who has access to them.
Weight Watchers holds its annual shareholder meeting today, which includes a presentation by departing board member Oprah Winfrey.
Old laws and the high cost of these drugs have been obstacles for wider coverage.
